These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31568801)

  • 1. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
    Wang H; Yao G; Chen X; Ouyang J; Yang J
    Diabetes Res Clin Pract; 2019 Nov; 157():107867. PubMed ID: 31568801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
    Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
    Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials.
    Chen W; Li P; Wang G; Chen Y; Wang B; Chen M
    Postgrad Med; 2019 Nov; 131(8):578-588. PubMed ID: 31414934
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
    J Diabetes Investig; 2021 Feb; 12(2):200-206. PubMed ID: 32623839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
    Kashiwagi A; Yoshida S; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Satomi H; Kosakai Y; Kawamuki K
    J Diabetes Investig; 2016 Jul; 7(4):544-54. PubMed ID: 27181576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
    Kashiwagi A; Kazuta K; Goto K; Yoshida S; Ueyama E; Utsuno A
    Diabetes Obes Metab; 2015 Mar; 17(3):304-8. PubMed ID: 24919820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
    Han KA; Chon S; Chung CH; Lim S; Lee KW; Baik S; Jung CH; Kim DS; Park KS; Yoon KH; Lee IK; Cha BS; Sakatani T; Park S; Lee MK
    Diabetes Obes Metab; 2018 Oct; 20(10):2408-2415. PubMed ID: 29862619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.
    Elgebaly A; Abdelazeim N; Abdelazeim B; El Ashal G; Mattar O; Namous L; Nasreldin N
    Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):56-72. PubMed ID: 29913526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
    Ishihara H; Yamaguchi S; Nakao I; Okitsu A; Asahina S
    Diabetes Obes Metab; 2016 Dec; 18(12):1207-1216. PubMed ID: 27436788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipragliflozin: first global approval.
    Poole RM; Dungo RT
    Drugs; 2014 Apr; 74(5):611-7. PubMed ID: 24668021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus.
    Fonseca VA; Ferrannini E; Wilding JP; Wilpshaar W; Dhanjal P; Ball G; Klasen S
    J Diabetes Complications; 2013; 27(3):268-73. PubMed ID: 23276620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
    Yang XP; Lai D; Zhong XY; Shen HP; Huang YL
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1149-58. PubMed ID: 25124541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
    Diabetes Obes Metab; 2019 Aug; 21(8):1990-1995. PubMed ID: 30993861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
    Alkabbani W; Gamble JM
    Drug Des Devel Ther; 2021; 15():3057-3069. PubMed ID: 34285473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
    Kitazawa M; Katagiri T; Suzuki H; Matsunaga S; H Yamada M; Ikarashi T; Yamamoto M; Furukawa K; Iwanaga M; Hatta M; Fujihara K; Yamada T; Tanaka S; Sone H
    Diabetes Obes Metab; 2021 Mar; 23(3):811-821. PubMed ID: 33416200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
    Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
    Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
    Zhuang Y; Song J; Ying M; Li M
    Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
    Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
    J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.